ALERT: Homology Medicines, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – FIXX – QNT Press Release


Robbins Geller Rudman & Dowd LLP announces that purchasers of Homology Medicines, Inc. (NASDAQ:FIXX) securities between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”) have until May 24, 2022 to seek appointment as lead plaintiff in Pizzuto v. Homology Medicines, Inc.No. 22-cv-01968 (CD Cal.). Commenced on March 25, 2022, the Homology Medicines class action lawsuit charges Homology Medicines as well as certain of its top executive officers with violations of the Securities Exchange Act of 1934.

If you suffered significant losses and wish to serve as lead plaintiff of the Homology Medicines class action lawsuit, please provide your information by clicking here. You can also contact attorney JC Sanchez of Robbins Geller by calling 800/449-4900 or via e-mail at Lead plaintiff motions for the Homology Medicines class action lawsuit must be filed with the court no later than May 24, 2022.

CASE ALLEGATIONS: Homology Medicines is a genetic medicines company and its lead product candidate is HMI-102, a gene therapy for the treatment of phenylketonuria (“PKU”) in adults that is in Phase I/II pheNIX clinical trial (the “HMI-102 Trial “). On June 10, 2019, Homology Medicines issued a press release announcing that it had commenced enrollment of the HMI-102 Trial.

The Homology Medicines class action lawsuit alleges that, throughout …

Full story available on


Source link

Recommended For You

About the Author: News Center